Barcelona, February 4th, 2021. New Luminor DCB evidence in complex BTK lesions has been presented on the main session of LINC 2021, the interventional course held on January 25th to 29th. MERLION outcomes show Luminor DCB outstanding performance in the most complex BTK lesions.
The aim of the MERLION trial was to evaluate the use of the Luminor drug coated balloon and the Angiolite BTK drug eluting stent from iVascular to minimise neointimal hyperplasia and restenosis in complex below the knee atherosclerotic lesions. Patients were recruited from a joint collaboration between Principal Investigator Dr Tjun Yip Tang, Senior Consultant from the Department of Vascular Surgery at Singapore General Hospital (SGH) and Dr Chuo Ren Leong, Senior Consultant Vascular Surgeon from Khoo Teck Puat Hospital (KTPH) in Singapore. Fifty patients with chronic limb threatening ischaemia (CLTI) were recruited between the two sites and at 1-year follow-up, a freedom from TLR of 82%, TLPP of 69%, amputation free survival of 74% and a complete wound healing rate of 66% were achieved in what is a challenging group of patients. There was excellent technical success and safety profile demonstrated with a low bail out tibial stenting rate.
Dr Tang (SGH) commented that “Even in frail patients with complex conditions whom we had recruited for the study, the device demonstrated promising safety and efficacy outcomes after lower limb revascularization at one year”.
Dr Leong (KTPH) added that “CLTI continues to pose a significant challenge to physicians and healthcare systems. In addition to best medical care, wound management and multidisciplinary approaches, the use of drug-eluting technology in the surgeon’s treatment armamentarium continues to show promise as a valuable adjunct in the battle for limb salvage. Our study has demonstrated good results in particular with regards to amputation free survival and complete wound healing rates in a cohort of patients with high rates of diabetes and end-stage renal failure”.
Luminor is a paclitaxel-coated balloon with platforms for different guidewire compatibility: 0.014”, 0.018” and 0.035”. It has been specifically designed for dilatation of stenosis located in the iliac, femoral, iliofemoral, popliteal, infrapopliteal, and renal arteries, as well as for the treatment of obstructive lesions of arteriovenous fistulas, either original or artificial.
The good outcomes obtained from these trials, prove that not all DCBs are the same. The unique iVascular proprietary coating nanotechnology, TransferTech. This technology differentiates Luminor DCB from others by covering the balloon surface with multiple and independent nanodrops layers, providing a flexible coating that adapts to the balloon movement and ensures the release of paclitaxel in the target lesion, without particle loss in the blood flow.
To learn more about Luminor DCB visit: https://ivascular.global/peripheral-endovascular/luminor-dcb/#
